Trastuzumab deruxtecan - Daiichi Sankyo

Drug Profile

Trastuzumab deruxtecan - Daiichi Sankyo

Alternative Names: DS-8201; DS-8201a

Latest Information Update: 28 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daiichi Sankyo Company; National Cancer Center (Tokyo)
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action DNA topoisomerase I inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Colorectal cancer; Gastric cancer; Uterine cancer
  • Phase I Solid tumours

Most Recent Events

  • 09 Apr 2018 Daiichi Sankyo plans a phase II trial for Non small cell lung cancer (Metastatic disease) in Japan , (JapicCTI183916)
  • 27 Mar 2018 Trastuzumab deruxtecan receives SAKIGAKE designation for Gastric cancer in Japan
  • 18 Jan 2018 Updated preliminary subgroup efficacy and adverse events data from a phase I trial in Solid tumours released by Daiichi Sankyo
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top